Full-Time
Confirmed live in the last 24 hours
Biotechnology company for aesthetic solutions
$37.26 - $51.27Hourly
Mid, Senior
Newark, CA, USA
5 days/week onsite
Revance Therapeutics, Inc. specializes in biotechnology with a focus on aesthetic and therapeutic solutions. The company primarily offers neuromodulators and dermal fillers, which are popular for minimally invasive cosmetic procedures. Neuromodulators, like botulinum toxin type A, help reduce wrinkles and treat muscle movement disorders, while dermal fillers restore volume and smooth facial lines. Revance is also exploring therapeutic uses for its products to enhance patient experiences in treating muscle movement and pain disorders. Additionally, the company has expanded into the fintech sector with the acquisition of HintMD, a platform that simplifies payment processes for aesthetic practices. This integration allows Revance to offer a comprehensive suite of services to support aesthetic practitioners. Unlike its competitors, Revance focuses on differentiated products and improved patient outcomes, aiming to lead the premium aesthetics market.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Nashville, Tennessee
Founded
1999
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Unlimited Paid Time Off
401(k) Company Match
Professional Development Budget
Evolus has strategically targeted a younger audience with its wrinkle treatment Jeuveau, setting itself apart from competitors like Revance and AbbVie, which usually focus on clients in their 40s.
In addition, under the Distribution Agreement, Revance is required to meet certain minimum purchase obligations and certain minimum expenditure requirements and either party may terminate the Distribution Agreement in the event of "a material breach by the other party."
Crown offer of $3.65 per share is the only offer available to Revance stockholders. Crown offer unanimously approved by the Revance Board of Directors. Teoxane withdraws its previous proposal, says it will tender its 6.2% stake in Revance into Crown tender
Revance Therapeutics is set to go private with Crown Laboratories by Feb. 6. Crown has increased its offer to $3.65 per share, a 17% rise from the previous $3.10 offer. The deal, endorsed by Revance's board, is the only fully-financed offer available. The initial $6.66 offer was paused due to a breach with Teoxane, but a settlement has been reached. Revance's shares were trading at $3.63, with a 52-week range of $2.30-$7.56. The offer is valid until Feb. 4.
From Washington, DC but with Oak Ridge ties: Teresa Robbins has been named as the Acting Administrator of the National Nuclear Security Administration (NNSA). Prior to this, she served as... The post News Notes | Acting Administrator of National Nuclear Security Administration has Oak Ridge ties appeared first on Teknovation.biz.